scholarly journals Impact and acceptability of self-consent procedures for the school-based human papillomavirus vaccine: a mixed-methods study protocol

BMJ Open ◽  
2018 ◽  
Vol 8 (3) ◽  
pp. e021321 ◽  
Author(s):  
Suzanne Audrey ◽  
Harriet Batista Ferrer ◽  
Joanne Ferrie ◽  
Karen Evans ◽  
Michael Bell ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Young Women ◽  
Hpv Vaccination ◽  
Health Information System ◽  
Routine Data ◽  
School Staff ◽  
Parental Consent ◽  
Human Papillomavirus Vaccine ◽  
Incidence And Mortality ◽  
New Procedures

IntroductionThe human papillomavirus (HPV) vaccine, administered in early adolescence, can substantially reduce cervical cancer incidence and mortality. However, lack of written parental consent is a key reason why some young women do not receive the vaccine. The national legal framework allows girls to be vaccinated without parental consent provided they are deemed Gillick competent, but there is some reticence about vaccinating without written parental consent. Self-consent procedures are being implemented in Bristol and South Gloucestershire. This study will examine the implementation, acceptability and impact of these new procedures.Methods and analysisStatistical analyses of routine data from Public Health England and the Child Health Information System will test if there has been an increase in HPV vaccination uptake in two ways: (a) Is there an increase when comparing before and after the change in our intervention sites? and (b) Does the percentage change in our intervention sites differ from comparison sites (similar to our intervention sites in terms of initial HPV uptake, ethnicity and deprivation levels) in England where no such intervention took place and how? For the process evaluation, we will develop a logic model and use questionnaires, observations and audio-recorded interviews with young women, school nurses, school staff and parents to examine the context, implementation of self-consent and response to the new procedures.Ethics and disseminationThe University of Bristol Faculty of Health Sciences Research Ethics Committee and the National Health Service Health Research Authority provided approvals for the study. We will produce a report with recommendations about self-consent procedures in conjunction with key stakeholders. At least two papers will be written for publication in peer-reviewed journals and for conference presentations. A summary of results will be shared with participating immunisation nurses, school staff, young people and parents as requested.Trial registration numberISRCTN49086105; Pre-results.

scholarly journals Implementing new consent procedures for schools-based human papillomavirus vaccination: a qualitative study

2021 ◽  
Vol 2 (2) ◽  
pp. 85-93
Author(s):  
Suzanne Audrey ◽  
Karen Evans ◽  
Michelle Farr ◽  
Joanne Ferrie ◽  
Julie Yates ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Young Women ◽  
Thematic Analysis ◽  
Local Authority ◽  
Health Inequities ◽  
Parental Consent ◽  
Structured Interviews ◽  
Human Papillomavirus Vaccination ◽  
School Based ◽  
New Procedures

Background The requirement for written parental consent for school-based human papillomavirus vaccination programme in England can act as a barrier to uptake for some young women, with the potential to exacerbate health inequities. Aims To consider the practicalities and implications of implementing new consent procedures, including parental telephone consent and adolescent self-consent, in two local authority areas in the southwest of England. Methods Digitally recorded, semi-structured interviews were conducted with 53 participants, including immunisation nurses, school staff, young people, and parents. All interviews were fully transcribed and thematic analysis was undertaken. Results Parental telephone consent was welcomed by the immunisation nurses, parents, and young women in the study. Adolescent self-consent was rare. Greater understanding of the barriers to uptake outside of mainstream school-based sessions is needed to further address inequalities in uptake. Conclusions The new procedures generally worked well but some important barriers to vaccination uptake remain.

Attitudes about human papillomavirus vaccine in young women

2003 ◽  
Vol 14 (5) ◽  
pp. 300-306 ◽  
Author(s):  
Jessica A Kahn ◽  
Susan L Rosenthal ◽  
Tara Hamann ◽  
David I Bernstein
Keyword(s):  
Human Papillomavirus ◽  
Young Women ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Human Papillomavirus Vaccine ◽  
Chi Square ◽  
Positive Attitudes ◽  
Number Of Sexual Partners ◽  
Papillomavirus Vaccine ◽  
To Receive

Human papillomavirus (HPV) vaccines are under investigation, but little is known about attitudes regarding vaccination. The aims of this study were to identify attitudes about and intention to receive an HPV vaccine in young women using a theory-based model. Young women ( n=52, mean age 25 years, range 18-30 years, 35% Black/Non-Hispanic) completed a survey assessing knowledge, attitudes about HPV vaccination, and risk behaviours. Associations between attitudes and intention to receive the vaccine were assessed using Mann-Whitney U or chi-square tests. Subjects reported positive attitudes about receiving an HPV vaccine and high intention to receive the vaccine both for themselves and their daughters. Variables associated significantly with intention included knowledge ( P=0.004), personal beliefs about vaccination ( P=0.004), belief that others would approve of vaccination ( P=0.005), and higher number of sexual partners ( P=0.028). Information on attitudes about HPV vaccination and predictors of intention to receive a vaccine may guide immunization initiatives for young adults.

scholarly journals Predictors of Human Papillomavirus Vaccine uptake or intent among parents of preadolescents and adolescents

2017 ◽  
Vol 7 (6) ◽  
pp. 35 ◽  
Author(s):  
Kimberlee Dayal ◽  
Sarah Robinson ◽  
Jessica Schoening ◽  
Mary Catherine Smith ◽  
Son Chae Kim
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Parental Education ◽  
Hpv Vaccination ◽  
College Education ◽  
Vaccine Effectiveness ◽  
Vaccine Uptake ◽  
Human Papillomavirus Vaccine ◽  
Hpv Knowledge ◽  
Hpv Vaccine Uptake

Aim: The aim of this study was to examine predictors of human papillomavirus (HPV) vaccine uptake or intent among parents of pre-adolescents and adolescents.Methods: A cross-sectional descriptive study was conducted among parents of girls aged 9 to 18 years, visiting two primary care clinics in central Texas from September to November 2015. Pearson’s product-moment correlation procedures and path analyses based on Health Belief Model were performed.Results: Path analysis showed that provider recommendation for HPV vaccination (β = 0.37; p < .001) and perceived HPV vaccine harm (β = -0.48; p < .001) had statistically significant direct effects on HPV vaccine uptake or intent. The perceived HPV vaccine effectiveness was directly influenced by HPV knowledge (β = 0.39; p < .001), empowerment in parent-provider relationships (β = 0.30; p = .006) and parental college education (β = 0.23; p = .039).}Conclusions: Together with parental empowerment fostering an equal partnership with providers, targeted education to improve parental HPV knowledge may convince them of the HPV vaccine effectiveness. This, in turn, may help them put the perceived HPV vaccine harm in proper perspective and allow them to make informed decisions regarding the timely HPV vaccination of their children. Because provider recommendation is one of the most important contributing factors for HPV vaccine uptake or intent, parental education and recommendations from nurses will help reduce the knowledge gaps and empower parents to make the timely decisions to vaccinate their children.

Challenges to Human Papillomavirus Vaccine Acceptability among Women in South India: An Exploratory Study

2021 ◽  
Author(s):  
Pooja Shah ◽  
Veena Shetty ◽  
Maithri Ganesh ◽  
Avinash K. Shetty
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Exploratory Study ◽  
Social Stigma ◽  
Hpv Vaccination ◽  
Scale Up ◽  
Vaccine Safety ◽  
Vaccine Uptake ◽  
Human Papillomavirus Vaccine ◽  
Barriers And Challenges

Cervical cancer is the second leading cause of cancer and one of the leading causes of cancer-related death in women in India. Human papillomavirus (HPV) vaccine uptake in India is low due to cost, low awareness of HPV, social stigma, and other factors. We assessed the awareness, attitudes, and beliefs regarding HPV and HPV vaccination and explored the barriers and challenges to HPV vaccine intent among women in Mangalore, India. An exploratory study was conducted using two focus group discussions (FGDs) and six in-depth one-on-one interviews. FGD-1 comprised nine women aged 18 to 26 years, and FGD-2 comprised seven women aged 27 to 45 years. The FGDs were recorded, transcribed, and analyzed using thematic content analysis. Themes identified were limited knowledge of HPV and vaccine, stigma associated with receiving HPV vaccine, vaccine safety concerns, and cost as a barrier to receiving vaccine. Participants expressed desire for physician and government recommendation of the HPV vaccine to validate vaccine intent. Contrasting themes between the two FGDs include support for vaccination at a younger age and lower perception of stigma and judgment in the 18- to 26-year-old group; however, participants in the 27- to 45-year-old group support vaccination at an older age and endorse greater fear of stigma and judgment associated with obtaining vaccination. Education regarding HPV-associated diseases and the HPV vaccine for the general public, physicians, and government officials in conjunction with lowering vaccine cost, improving vaccine access, and encouraging strong physician recommendations are key strategies to scale up HPV vaccine implementation in India.

scholarly journals Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study

2020 ◽  
Vol 18 (1) ◽  
Author(s):  
Ingrid Herta Rotstein Grein ◽  
Natalia Balera Ferreira Pinto ◽  
Noortje Groot ◽  
Camila Bertini Martins ◽  
Aline Lobo ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Disease Activity ◽  
Juvenile Dermatomyositis ◽  
Hpv Vaccination ◽  
Dose Schedule ◽  
Current Therapy ◽  
Human Papillomavirus Vaccine ◽  
Serum Samples ◽  
The Third ◽  
Clinical Trials Registry

Abstract Background Concerns about the safety and efficacy of vaccines in patients with autoimmune diseases (AID) have led to contradictions and low vaccination coverage in this population, who are at a higher risk of infections, including by human papillomavirus (HPV). Although HPV vaccines have been recommended for immunocompromised patients, there is still a lack of data to support its use for AID patients, such as juvenile dermatomyositis (JDM) patients. The aim of this study was to assess the safety and immunogenicity of the quadrivalent HPV (qHPV) vaccine in a cohort of JDM patients. Methods JDM patients aged from 9 to 20 years and healthy controls (HC) were enrolled to receive a 3-dose schedule of qHPV vaccine from March/2014 to March/2016. Study visits were performed before the first dose, 1 month after the second and third doses, and 6 months after the third dose. Participants completed a diary of possible adverse events for 14 days following each dose of vaccination (AEFV). Disease activity and current therapy were analyzed at each visit for JDM patients. In addition, serum samples from all participants were collected to test antibody concentrations against HPV16 and 18 at each visit. Participant recruitment was conducted in ten Brazilian centres. From 47 eligible JDM patients and 41 HC, 42 and 35, respectively, completed the 3-dose schedule of the vaccine, given that five JDM patients and two HC had received doses prior to their inclusion in the study. Results The AEFVs presented by the participants were mild and in general did not differ between JDM and HC groups. No severe AEFVs were related to the vaccination. Disease activity was stable, or even improved during the follow-up. One month after the third dose of the vaccine the JDM group presented seropositivity of 100% for HPV16 and 97% for HPV18, similarly to the HC group, who presented 100% for both serotypes (p = 1.000). Six months after the third dose the seropositivity for the patient group was 94% for both HPV types. Conclusions The HPV vaccination in this cohort of JDM patients was safe and immunogenic. Since the seropositivity against HPV16 and 18 was very high after the 3-dose schedule, this regimen should be recommended for JDM patients. Trial registration Brazilian Clinical Trials Registry, number: RBR-9ypbtf. Registered 20 March 2018 – Retrospectively registered.

scholarly journals Predictors of Initial Uptake of Human Papillomavirus Vaccine Uptake Among Rural Appalachian Young Women

2013 ◽  
Vol 34 (1-2) ◽  
pp. 71-80 ◽  
Author(s):  
Baretta R. Casey ◽  
Richard A. Crosby ◽  
Robin C. Vanderpool ◽  
Mark Dignan ◽  
Wallace Bates
Keyword(s):  
Human Papillomavirus ◽  
Young Women ◽  
Vaccine Uptake ◽  
Human Papillomavirus Vaccine ◽  
Papillomavirus Vaccine ◽  
Initial Uptake

scholarly journals Immunogenicity of a Two-Dose Human Papillomavirus Vaccine Schedule in HIV-Infected Adolescents with Immune Reconstitution

Vaccines ◽  
2022 ◽  
Vol 10 (1) ◽  
pp. 118
Author(s):  
Supattra Rungmaitree ◽  
Charin Thepthai ◽  
Zheng Quan Toh ◽  
Noppasit Musiwiraphat ◽  
Alan Maleesatharn ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Immune Reconstitution ◽  
Geometric Mean ◽  
Hpv Vaccination ◽  
Human Papillomavirus Vaccine ◽  
Hpv 16 ◽  
Cell Counts ◽  
Increased Risk ◽  
2D And 3D ◽  
Hpv 18

HIV-infected patients are at increased risk of human papillomavirus (HPV) acquisition and HPV-associated diseases. This study set out to determine whether a two-dose (2D) HPV vaccination schedule was sufficient in HIV-infected adolescents with immune reconstitution (IR) following antiretroviral treatment. Participants aged 9–15 years who had CD4 cell counts > 500 cells/mm3 and HIV-1 RNA < 40 copies/mL for at least one year were assigned to the 2D schedule, while older participants or those without IR received a three-dose (3D) schedule. Antibodies to HPV-16 and -18 were measured using a pseudovirion-based neutralization assay. A total of 96 subjects were enrolled; 31.3% and 68.7% received the 2D and 3D schedule, respectively. Of these, 66.7% and 57.6% of the 2D and 3D participants, respectively, were male. The seroconversion rates for HPV-16 and HPV-18 were 100% in all cases, except for HPV-18 in males who received the 3D schedule (97.4%). In males, the anti-HPV-16 geometric mean titers (GMTs) were 6859.3 (95% confidence interval, 4394.3–10,707.1) and 7011.1 (4648.8–10,573.9) in the 2D and 3D groups (p = 0.946), respectively, and the anti-HPV-18 GMTs were 2039.3 (1432.2–2903.8) and 2859.8 (1810.0–4518.4) in the 2D and 3D (p = 0.313) groups, respectively. In females, the anti-HPV-16 GMTs were 15,758.7 (8868.0–28,003.4) and 26,241.6 (16,972.7–40,572.3) in the 2D and 3D groups (p = 0.197), respectively, and the anti-HPV-18 GMTs were 5971.4 (3026.8–11,780.6) and 9993.1 (5950.8–16,781.1) in the 2D and 3D groups (p = 0.271), respectively. In summary, a 2D schedule is as immunogenic in young adolescents with IR as a 3D schedule in older subjects and those without IR.

scholarly journals Sexual Health Variables and the Human Papillomavirus Vaccine

2009 ◽  
Vol 7 (2) ◽  
pp. 129-138
Author(s):  
Victoria Barry ◽  
Shannon B. Myers ◽  
Amy E. Sgrenci ◽  
Megan Lavery ◽  
Deirdra Frum ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Pap Smear ◽  
Hpv Vaccination ◽  
Transmitted Disease ◽  
The United States ◽  
Human Papillomavirus Vaccine ◽  
Cross Sectional Survey ◽  
Cross Sectional ◽  
Sexually Transmitted ◽  
Status Seeking

Recent strides have been made in developing vaccines to prevent contraction of the Human Papillomavirus (HPV), which is currently the most prevalent sexually transmitted disease in the United States. This study looked to investigate seven sexually relevant variables hypothesized to be related to a young woman's choice to receive the Gardasil® vaccine in order to prevent HPV contraction via a cross sectional survey. In a sample of 77 undergraduate women, we investigated the relationship between receipt of Gardasil® and the following variables: knowledge regarding HPV, relationship status, seeking gynecological services, having received an abnormal PAP smear, sexual activity status, number of sexual partners, and concern about contracting HPV. Logistical regression analysis and independent groups t-test revealed that none of these factors were related to actual receipt of the HPV vaccine in this sample. These results suggest the need for more research regarding potential practical barriers to HPV vaccination.

Sign in / Sign up

Export Citation Format

Share Document